GET DAILY SIGNALSPulmonx (LUNG) Shares Rise +35% After Q3 Turnaround
Key Takeaways
- Pulmonx shares rose roughly 35% over the past 30 days, climbing from about $1.96 to approximately $2.64 as of late October 2026.
- The rally followed third-quarter 2026 results that marked Pulmonx's first return to year-over-year global revenue growth.
- Q3 revenue increased 6% to $22.8 million, while the net loss narrowed 40% to $8.4 million, or $0.19 per share, beating consensus estimates.
- Cost reductions, a rebuilt U.S. sales organization, and the renewal of the company's China registration certificate underpinned the improved outlook.
- Analyst sentiment turned more constructive after the report, with Stifel raising its price target to $4 from $2.50 while maintaining a Buy rating.
- For additional detail on valuation, financials, and expectations, explore Pulmonx's Price Targets, Earnings, and Forecast pages.
- Investors can also review top-performing, curated strategies on the Trending AI Robots page.
Pulmonx (LUNG) Company Overview
Pulmonx Corporation (LUNG) is a commercial-stage medical technology company and a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Its flagship product, the Zephyr Endobronchial Valve, is designed to treat patients with severe emphysema who remain profoundly symptomatic despite medical management. The Zephyr Valve received U.S. Food and Drug Administration (FDA) Premarket Approval following its designation as a "breakthrough device" and is commercially available in more than 25 countries, where it is included in global treatment guidelines.
The company's portfolio also includes the Chartis Pulmonary Assessment System, the LungTraX Platform, and StratX Lung Analysis Reports, which help physicians assess patients and identify target lobes for treatment. I keep an eye on LUNG for its exposure to a large, underpenetrated emphysema market, its recurring catheter-based procedure model, and its pipeline opportunity through AeriSeal, a potential market-expanding therapy. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Price Performance
Over the last 30 days, LUNG advanced approximately 35%, moving from a closing price near $1.96 on September 28, 2026, to roughly $2.64 in late October 2026. For much of October, the stock traded in a relatively narrow range between about $1.75 and $1.98 before surging in response to the company's third-quarter earnings report released on October 27. From what I see, this kind of move often signals a shift in sentiment when fundamentals start to align.
The broader quarterly trend has also been positive, with the stock up roughly 21% over the trailing three-month period, according to market data compiled around the earnings release. Despite the recent rebound, LUNG remained lower on a year-to-date basis, reflecting the challenges the company faced earlier in 2026 before its commercial turnaround began to take hold.
Key Drivers Behind the Recent Rally
The primary catalyst was Pulmonx's third-quarter 2026 financial results. The company reported worldwide revenue of $22.8 million, up 6% year over year, representing its first return to global year-over-year growth since its current leadership team rejoined the company. U.S. revenue rose 7% to $14.9 million, while international revenue increased 5% to $7.9 million, or about 9% excluding China.
The results also showed meaningful progress toward profitability. Gross margin improved to 76% from 75%, operating expenses declined 18% to $24.9 million, and the adjusted EBITDA loss narrowed by nearly 60% to $3.5 million. The net loss shrank 40% to $8.4 million, or $0.19 per share, beating the consensus estimate of a $0.26 per-share loss, while revenue topped the roughly $21.9 million analyst consensus. One thing that stands out here is how quickly the cost discipline is translating into narrower losses.
Investor sentiment was further supported by analyst actions. Stifel raised its price target on Pulmonx to $4 from $2.50 while maintaining a Buy rating, and Canaccord Genuity reiterated a Buy recommendation. The company also announced that its China registration certificate had been renewed, allowing it to restart commercial activity in the region with shipments expected to resume by early next year. I’m watching this closely as China could add a meaningful tailwind.
Quarterly Performance Factors
Over the past quarter, LUNG's recovery has been driven by a multi-month operational reset. Management spent the year rebuilding its U.S. sales leadership team and filling open territories, and the company reported that substantially all open U.S. sales positions have now been filled. This contributed to the addition of eight new U.S. treating centers during the quarter and a return to U.S. revenue growth.
The company also restructured its credit facility earlier in 2026, extending debt maturity to 2031 and securing access to additional undrawn capital. Ongoing cost-reduction initiatives have lowered operating expenses and reduced expected cash burn, while clinical momentum—including five-year follow-up data from the LIBERATE pivotal trial and progress enrolling the CONVERT II IDE trial for AeriSeal—has reinforced the long-term growth narrative.
Looking Ahead: What to Watch
Looking ahead, investors are likely to focus on whether Pulmonx can sustain its return to growth. The company reiterated full-year 2026 revenue guidance of $90 million to $92 million and expects full-year gross margin of approximately 77%, with operating expenses guided to between $108 million and $109 million. The resumption of China shipments early next year represents a potential incremental revenue driver.
Additional factors to monitor include the pace of new U.S. treating center additions, continued progress enrolling the CONVERT II trial, and the company's ability to narrow losses and manage cash burn, which it expects to total roughly $22 million for 2026. Macroeconomic conditions, broader medical-device sector sentiment, and any changes in analyst estimates following the earnings report could also influence the stock's direction.
My Experience with Tickeron AI Trading Bots
In my own research process, I often review Tickeron’s AI Trading Bots to see how automated strategies are performing across different market conditions. These tools allow me to compare quantitative approaches side by side and identify setups that align with the fundamentals I’m tracking. It’s been helpful for stress-testing ideas without overcomplicating the workflow, especially when evaluating names like LUNG that are in turnaround phases.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LUNG in upward trend: price rose above 50-day moving average on October 28, 2026
LUNG moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend. In 32 of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on LUNG as a result. In 68 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for LUNG just turned positive on October 20, 2026. Looking at past instances where LUNG's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.
Following a +29.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where LUNG advanced for three days, in 214 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for LUNG crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LUNG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
LUNG broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LUNG entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.761) is normal, around the industry mean (3.824). P/E Ratio (-2.191) is within average values for comparable stocks, (1.677). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.932) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. LUNG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LUNG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement